Period:
Draw Mode:
| Volume | 50 |
|
|||||
| News | - | ||||||
| Day High | Low High |
||||||
| Day Low | |||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| Altimmune Inc | ALT | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.00 | 0.0% | 4.37 | 04:33:12 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 4.37 |
| Trades | Volume | Avg Volume | 52 Week Range |
|---|---|---|---|
| 1 | 50 | - | 3.83 - 23.49 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 04:29:06 | 50 | $ 4.50 | USD |
Altimmune Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 215.35M | 49.28M | 42.96M | $ -68.00k | $ - | -1.78 | 3.80 |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 953.42k | 10.30% |
Altimmune News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical ALT Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 4.25 | 4.97 | 4.14 | 4.43 | 2,873,216 | 0.12 | 2.82% |
| 1 Month | 12.00 | 12.145 | 4.14 | 6.55 | 3,033,365 | -7.63 | -63.58% |
| 3 Months | 14.71 | 17.17 | 4.14 | 9.58 | 1,848,473 | -10.34 | -70.29% |
| 6 Months | 12.64 | 17.17 | 4.14 | 10.58 | 1,589,493 | -8.27 | -65.43% |
| 1 Year | 6.30 | 23.49 | 3.83 | 11.63 | 1,739,124 | -1.93 | -30.63% |
| 3 Years | 3.04 | 35.10 | 2.80 | 13.24 | 1,840,316 | 1.33 | 43.75% |
| 5 Years | 1.19 | 36.25 | 0.245 | 11.00 | 1,423,634 | 3.18 | 267.23% |
Altimmune Description
| Altimmune Inc is engaged on developing treatments for obesity and liver diseases. The Company's pipeline includes next generation peptide therapeutics for obesity and non-alcoholic steatohepatitis (NASH) (for both, pemvidutide, formerly known as ALT-801), and for chronic hepatitis B (HepTcell). The Company is managed and operates as a single business focused on the research and development of treatments for various diseases and disorders, and vaccines. |